# US 2005/0032124 A1 · Identification of genotype-selective agents for treating Huntington's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032124 A1
- Document ID: US20050032124A1
- Status: Published application
- Kind: A1
- Application number: 10/767,591
- Filed: 2004-01-29
- Published: 2005-02-10
- Earliest claimed: 2003-01-29
- Inventors: Brent Stockwell; Benjamin Hoffstrom; Hemant Varma
- Web page: https://patentgrep.com/patent/US20050032124A1

## CPC

- G01N 33/5014: {for testing toxicity}
- G01N 33/5058: {Neurological cells}
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relate to methods of identifying a genotype-selective agent. In certain embodiments, the invention relates to agents that selectively suppress huntingtin-induced toxicity to engineered neuronal cells.

## Claims

### Claim 1

A method of identifying an agent that selectively suppresses toxicity to a neuronal cell, comprising:
(a) contacting test cells, which are engineered neuronal cells, with a candidate agent;
(b) determining viability of test cells contacted in (a) with the candidate agent; and
(c) comparing the viability of test cells determined in (b) with an appropriate control,
wherein if the viability of the test cells is more than that of the control cells, then an agent that selectively suppresses toxicity to neuronal cells is identified.

### Claim 2 (depends on 1)

The method of claim 1, comprising further assessing, in an appropriate animal model, the selective toxicity-suppressive activity of the agent that is identified.

### Claim 3 (depends on 1)

The method of claim 1, wherein the engineered neuronal cells express a mutant huntingtin protein.

### Claim 4 (depends on 1)

The method of claim 1, wherein the candidate agent is a tubulin inhibitor.

### Claim 5 (depends on 1)

A method of treating or preventing a neurodegenerative disorder associated with polyglutamine (polyQ) expansion, in an individual, comprising administering to the individual a therapeutically effective amount of an agent identified by the method of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the neurodegenerative disorder is selected from the group consisting of: Huntington's disease, spinobulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and the spinocerebellar ataxias type 1, 2, 3, 6, 7, and 17.

### Claim 7 (depends on 5)

The method of claim 5, wherein the agent is a tubulin inhibitor.
